Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Non-Current Deferred Tax Liability (2018)

Karyopharm Therapeutics (KPTI) has disclosed Non-Current Deferred Tax Liability for 1 consecutive years, with $15.5 million as the latest value for Q4 2018.

  • For the quarter ending Q4 2018, Non-Current Deferred Tax Liability changed N/A year-over-year to $15.5 million, compared with a TTM value of $15.5 million through Dec 2018, changed N/A, and an annual FY2018 reading of $15.5 million, changed N/A over the prior year.
  • Non-Current Deferred Tax Liability was $15.5 million for Q4 2018 at Karyopharm Therapeutics.
  • Across five years, Non-Current Deferred Tax Liability topped out at $15.5 million in Q4 2018 and bottomed at $15.5 million in Q4 2018.